Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2016-03-15 Annual Report
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
FORM 10-K
Annual Report FY 2015
2016-03-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text mentions an updated corporate presentation posted on the company's website and a press release about FDA feedback. The document is short (3254 characters) and primarily serves to announce these events and exhibits rather than provide detailed financial data or full reports. There is no detailed financial statement or comprehensive report content. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2016-03-08 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-02-23 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content specifically reports an extension of the FDA target date for action on a New Drug Application, which is a material event but not a financial report or earnings release. The document includes a press release as an exhibit. The length is 2643 characters, which is relatively short and primarily an announcement of an event rather than a detailed report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2016-02-20 English
TITAN PHARMACEUTICALS, INC.-AMEND. #1
Major Shareholding Notification
2016-02-12 English
Major Shareholding Notification 2016
Major Shareholding Notification
2016-02-11 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.